Wells Fargo lowered the firm’s price target on Zentalis (ZNTL) to $6 from $8 and keeps an Equal Weight rating on the shares. The firm believes shares will remain depressed as azeno will need additional dose ranging prior to getting buy-in from the FDA on an accelerated approval path in PROC. With no real data catalysts until 2026, Wells doesn’t see a path for upside in the next twelve months.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis price target lowered to $10 from $20 at H.C. Wainwright
- Zentalis price target lowered to $10 from $20 at Oppenheimer
- Zentalis Pharmaceuticals Announces New Study for Azenosertib
- Zentalis presents updated clinical data on azenosertib
- Zentalis to reduce workforce by 40% in business restructuring